Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

LAB USA, INC.

NPI: 1841332780 · HAVERHILL, MA 01830 · Clinical Medical Laboratory · NPI assigned 02/13/2007

$4.51M
Total Medicaid Paid
199,882
Total Claims
159,394
Beneficiaries
65
Codes Billed
2018-01
First Month
2024-04
Last Month

Provider Details

Authorized OfficialAFREEDI, MOHAMMAD (CEO AND PRESIDENT)
NPI Enumeration Date02/13/2007

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 60,290 $1.11M
2019 44,118 $1.16M
2020 21,485 $545K
2021 47,971 $917K
2022 24,118 $687K
2023 1,706 $83K
2024 194 $3K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 42,412 25,183 $2.16M
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 25,645 10,802 $1.02M
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 4,719 3,680 $335K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 2,050 1,047 $156K
G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source 4,646 3,603 $97K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 3,634 3,478 $74K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 3,632 3,478 $74K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 3,909 3,777 $63K
85025 Blood count; complete (CBC), automated, and automated differential WBC count 13,369 12,802 $59K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 405 167 $54K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 2,102 1,453 $44K
84443 Thyroid stimulating hormone (TSH) 5,023 4,856 $42K
80061 Lipid panel 10,210 9,958 $39K
80053 Comprehensive metabolic panel 10,498 10,334 $33K
82607 3,477 3,346 $29K
86003 224 206 $23K
83036 Hemoglobin; glycosylated (A1C) 4,827 4,671 $22K
83013 694 669 $18K
ATP14 1,836 1,822 $13K
80050 General health panel 963 959 $12K
ATP18 1,594 1,589 $10K
80074 309 297 $10K
83550 1,775 1,687 $9K
84439 1,695 1,618 $9K
82746 1,034 969 $9K
82728 1,131 1,061 $9K
83540 2,110 2,023 $8K
84481 689 634 $7K
ATP17 1,386 1,381 $7K
87086 Culture, bacterial; quantitative colony count, urine 1,438 1,380 $7K
80048 Basic metabolic panel (calcium, ionized) 2,971 2,899 $6K
84153 566 539 $6K
86677 807 783 $6K
81003 4,577 4,416 $5K
86592 2,264 2,151 $5K
36415 Collection of venous blood by venipuncture 17,626 16,558 $5K
86703 609 584 $5K
86803 647 616 $4K
83735 1,498 1,468 $4K
80076 1,854 1,771 $3K
ATP15 430 427 $3K
82977 2,116 2,053 $3K
83014 734 703 $2K
ATP08 383 373 $2K
82550 907 888 $2K
87340 285 265 $1K
83655 117 116 $957.85
81001 376 359 $894.73
ATP19 78 78 $798.70
84480 516 460 $685.74
86430 166 165 $673.17
84550 362 348 $563.60
85651 191 184 $472.14
81015 1,872 1,797 $415.84
82947 136 134 $348.45
ATP16 32 32 $315.81
87070 19 19 $159.84
84703 15 15 $90.96
80051 28 27 $73.82
ATP04 27 27 $72.40
82565 69 62 $51.28
84100 123 102 $36.08
ATP03 14 14 $34.25
84520 14 14 $17.42
84075 17 17 $5.34